Tad Landowski

Visionary commercial executive with over 20 years of success driving transformational growth across rare disease, immunology, respiratory, endocrinology, eye care, and dermatology markets. Proven expertise in leading high-performing teams, launching blockbuster brands, and executing strategic sales initiatives in complex, regulated environments. Known for fostering inclusive, high-accountability cultures and building strong cross-functional partnerships that drive revenue and market leadership.

• Introductory Sommelier: The Court of Master Sommeliers (CMS)
• Artificial Intelligence: Business Strategies and Applications: UC Berkeley Executive Education
• Business Analytics: Data-Driven Strategy: Kellogg Executive Education | Northwestern University

• Successfully scaled national and regional sales teams across multiple blockbuster brands.
• Helped expand two Cosentyx teams (Dermatology and Rheumatology) at Novartis.
• Helped build out launch plan for the launch of Soolantra at Galderma, exceeding $100M in sales in under two years.
• Launched a new endocrinology sales force for TEPEZZA at Amgen, delivering $1.6B in net sales in 2024.
• Worked on multi-billion-dollar brands including Cosentyx, Xiidra, Xolair, and TEPEZZA.
• Deep expertise in hiring, training, and developing high-performing field teams and leadership talent.
• Known for execution excellence, cross-functional alignment, and sustaining performance post-launch.
• Demonstrated operational excellence and strategic agility in both large enterprises and fast-paced, evolving organizations.

• Led two sales teams, including three second-line managers, Chief of Staff, 18 first-line managers, and 126 sales associates at Amgen.
• Led a rare disease sales organization with a start-up mindset, building infrastructure, sales processes, KPIs, and incentive plans aligned with corporate goals.
• Led two separate sales teams at Novartis resulting in 3B+ in net sales in 2024.
• Directed go-to-market strategies for immunology, ophthalmology, and respiratory products, ensuring cross-functional coordination and market penetration at Novartis.
• Oversaw KPI design, IC plan development, and field team engagement strategies to support aggressive market goals at Novartis.
• Cultivated a culture of continuous improvement by restructuring the sales model and structure for the Xolair® sales team, enabling the brand to achieve more with fewer resources, promoting 15% of the field sales leaders, and pioneering the adoption of an innovative customer-centric model.
• Helped transform the Strategic Account team, scaling its impact from ten strategic account managers to fifty influential Thought Leader Liaisons throughout the U.S. immunology business unit.
• Strategic leadership role in the launch of a new rosacea product, Soolantra®, in the U.S. market, which generated over $100 million in sales within two years at Galderma.